Canaccord Genuity Reiterates Buy on Avanir (AVNR) as Drug Sales Ramp
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avanir (AVNR) Preliminary Q4 Sales Top Views; Initiates FiH Phase I for AVP-786
November 27, 2012 8:42 AM ESTAvanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary results for the quarter ended September 30, 2012.
Financial Update
Based on preliminary results for the fourth fiscal quarter ended September 30, 2012, Avanir estimates:
* Gross revenue for NUEDEXTA® of $15.4 million, representing an increase of approximately 26% over the prior quarter. The Street was looking for total sales of $12.7 million.
* Total... More
